← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT07038096
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Trial Parameters
Condition Small Cell Lung Cancer
Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 350
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2025-09-23
Completion 2027-09
All Conditions
Interventions
ZG006ZG005
Brief Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Eligibility Criteria
Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * Male or female 18-70 years of age. * Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology. * Eastern Cooperative Oncology Group (ECOG) 0 to 1. * Life expectancy \> 3 months. Exclusion Criteria: * The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Related Trials
NCT06717243
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STR
View Trial →
NCT05419076
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
View Trial →
NCT06486428
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
View Trial →